PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

ARCH Venture Partners

Chicago, ILARCH-VENTURE
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Deep science VC spinning out companies from universities and national labs.

Classification
Slugarch-venture
HQChicago, IL
Stage FocusSeries A through growth stage in life sciences (biotech, …
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

ARCH is the real deal for deep science and biotech - they've been doing this since before most VCs knew what DNA sequencing was. Bob Nelsen is genuinely one of the smartest biotech investors alive and the team has serious technical chops. They're patient capital that understands long R&D cycles, but they're also tough - they'll push you hard on milestones and scientific rigor. Not the fund for consumer apps or quick flips, but if you're building something that requires PhD-level science and 7-10 year timelines, they're gold standard. They do their homework and won't waste your time if the science doesn't check out.

KEY TAKEAWAYS
  • Best for: Deep tech and biotech with serious IP and long development cycles
  • Watch out for: They demand rigorous scientific validation and clear milestone planning
  • Known for: Patient capital, technical expertise, and legendary biotech track record
Investment Thesis

ARCH backs breakthrough science and technology companies that can transform entire industries. They focus on deep tech, life sciences, and frontier technologies with strong intellectual property moats and defensible competitive advantages.

Stage & Sector Focus

Series A through growth stage in life sciences (biotech, medtech, digital health) and deep tech (AI, quantum, materials science). They write $5-25M checks and have patient capital for long development cycles.

Notable Portfolio
IlluminaExact SciencesAllscriptsSomatic TherapeuticsLyftCodexisKythera BiopharmaceuticalsSage Therapeutics
Key Partners
Bob Nelsen
Co-founder and Managing Director

Co-founded ARCH in 1986 and is a legend in biotech investing. Known for taking big swings on transformative science and has been on dozens of boards. Founders respect his deep technical knowledge and long-term thinking.

Keith Crandell
Managing Director

Former McKinsey consultant turned VC with 20+ years at ARCH. Focuses on healthcare IT and services. Known as operationally savvy and hands-on with portfolio companies on business model development.

Kristina Burow
Managing Director

Former entrepreneur who built and sold health tech companies before joining ARCH. Leads digital health investments and is known for understanding both the clinical and commercial sides of healthcare.

Have a specific question about ARCH Venture Partners?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1